Verastem Förvaltning
Förvaltning kriterier kontrolleras 4/4
Verastem VD är Dan Paterson, utsedd i Jun 2019, har en mandatperiod på 7.08 år. totala årliga ersättningen är $ 2.40M, bestående av 28.1% lön 71.9% bonusar, inklusive företagsaktier och optioner. äger direkt 0.28% av företagets aktier, värda $ 1.48M. Den genomsnittliga mandatperioden för ledningsgruppen och styrelsen är 2.5 år respektive 4.9 år.
Viktig information
Dan Paterson
Verkställande direktör
US$2.4m
Total ersättning
| VD-lön i procent | 28.08% |
| Anställning som VD | 7.1yrs |
| Ägande av VD | 0.3% |
| Ledningens genomsnittliga anställningstid | 2.5yrs |
| Styrelsens genomsnittliga mandatperiod | 4.9yrs |
Senaste uppdateringar av ledningen
Recent updates
Uppdatering av berättelse • Jun 26
VSTM: Future KRAS Data And Pancreatic Trial Progress Will Drive Repricing
The Verastem analyst price target has been revised lower, with a fair value estimate moving from about $14.00 to about $8.85 as analysts factor in a less favorable long thesis in a more crowded competitive space and updated post-earnings models. Analyst Commentary on Verastem Recent Street research on Verastem reflects a more cautious tone, with several bearish analysts trimming their fair value assumptions and reassessing the long thesis after recent earnings and competitive updates.Analysartikel • May 11
Analysts Are Updating Their Verastem, Inc. (NASDAQ:VSTM) Estimates After Its First-Quarter Results
It's been a sad week for Verastem, Inc. ( NASDAQ:VSTM ), who've watched their investment drop 18% to US$4.89 in the...
Ny berättelse • Jan 22
RAS And MAPK Cancer Pipeline Will Drive Long Term Upside Potential
Catalysts About Verastem Verastem is an oncology company focused on therapies for RAS and MAPK pathway driven cancers, including KRAS mutated recurrent low grade serous ovarian cancer. What are the underlying business or industry changes driving this perspective?Analysartikel • Dec 26
Verastem, Inc.'s (NASDAQ:VSTM) Share Price Is Still Matching Investor Opinion Despite 26% Slump
Verastem, Inc. ( NASDAQ:VSTM ) shareholders won't be pleased to see that the share price has had a very rough month...Seeking Alpha • Jul 16
Verastem: The Market Is Ignoring The Progress
Summary FDA approval of AVMAPKI FAKZYNJA CO-PACK marks a transformative milestone, positioning Verastem as a commercial-stage leader in KRAS-mutant LGSOC treatment. Verastem's strong cash position and promising pipeline, including VS-7375 for KRAS G12D, offer significant upside with multiple near-term catalysts ahead. Risks include slow commercial uptake, pipeline uncertainty, and potential future dilution, but current valuation under $5 presents an attractive entry point. I maintain a 3/5 conviction, plan to add to my position below $5.75, and aim to hold long-term as VSTM targets KRAS-driven cancers. Read the full article on Seeking AlphaSeeking Alpha • May 26
Verastem: Narrowed Market And Less Compelling Efficacy Warrant Rating Downgrade
Summary Verastem's stock plummeted after updates showed reduced efficacy in cancer treatment trials, causing a reassessment of strategy. Updated clinical trial results show a significant drop in response rates, suggesting less robust efficacy than earlier believed. Financially, Verastem has only a year of cash runway and faces significant dilution risks to extend it. Downgrade the recommendation to 'hold' due to increased risks and market volatility associated with microcap stocks. Read the full article on Seeking AlphaSeeking Alpha • Sep 13
Verastem: Moving Forward
Summary Today, we circle back on a small oncology outfit called Verastem, Inc. The company is steadily advancing its pipeline targeting both LGSOC and NSCLC and Verastem secured funding this year to carry out its multiple trials. An investment analysis follows in the paragraphs below. Don't waste your time with explanations: people only hear what they want to hear. ― Paulo Coelho We haven't taken a look at Verastem, Inc. (NASDAQ:VSTM) since an article on this small biotech name early last year. There has been some news flow around the company since then and Verastem recently posted a new investor presentation, so it seems a good time to circle back on this story. Seeking Alpha Company Overview Verastem is based out of Massachusetts. The company developed 'Copiktra' which received FDA approval for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)/follicular lymphoma in the summer of 2018. The company soon after sold the global rights to this compound for a significant upfront payment. It continues to collect royalties and milestone payments from this arrangement. August Company Presentation The company is currently focused on establishing its candidate 'VS-6766' as the backbone therapy for RAS-driven solid tumors. This is how management describes VS-6766 on its last earnings press release. August Company Presentation VS-6766 is a RAF/MEK clamp that induces inactive complexes of MEK with ARAF, BRAF and CRAF potentially creating a more complete and durable anti-tumor response through maximal RAS pathway inhibition. In contrast to other MEK inhibitors, VS-6766 blocks both MEK kinase activity and the ability of RAF to phosphorylate MEK. This unique mechanism allows VS-6766 to block MEK signaling without the compensatory activation of MEK that appears to limit the efficacy of other inhibitors. August Company Presentation There is a high unmet need in the cancers VS-6766 is targeting in development. The stock currently trades around $1.25 a share and sports an approximate market capitalization of $230 million. August Company Presentation Developmental Progress August Company Presentation As can be seen above, VS-6766 is in numerous combination therapy trials and as a monotherapy focused on Non-Small Cell Lung Cancer (NSCLC) and Gynecologic Oncology. Most of these studies pair VS-6766 with another Verastem pipeline asset Defactinib, a FAK inhibitor. The most critical of these are RAMP 201 and RAMP 202. Both are registration-directed phase 2 studies and were initiated in the fourth quarter of 2020. RAMP 201 is targeting low-grade serous ovarian carcinoma or LGSOC and RAMP 2022 is targeting NSCLC. August Company Presentation Both studies should see top line results out in 2023. In mid-June, interim results came out from the RAMP 201 trial that showed VS-6766 as both a standalone therapy and in combination with defactinib showed encouraging efficacy with confirmed responses in patients with recurrent LGSOC, regardless of KRAS mutation. August Company Presentation The company is also conducting a trial called RAMP 203 in conjunction with Amgen (AMGN). This phase 1/2 with evaluate the 'tolerability and efficacy of VS-6766 in combination with Lumakras in patients with KRAS G12C-mutant NSCLC who have not been previously treated with a KRAS G12C inhibitor as well as in patients who have progressed on a KRAS G12C inhibitor.'Analysartikel • Sep 01
Health Check: How Prudently Does Verastem (NASDAQ:VSTM) Use Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analys av ersättningar till VD
| Datum | Total ersättning | Lön | Företagets resultat |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$194m |
| Dec 31 2025 | US$2m | US$674k | -US$209m |
| Sep 30 2025 | n/a | n/a | -US$241m |
| Jun 30 2025 | n/a | n/a | -US$167m |
| Mar 31 2025 | n/a | n/a | -US$149m |
| Dec 31 2024 | US$3m | US$648k | -US$131m |
| Sep 30 2024 | n/a | n/a | -US$93m |
| Jun 30 2024 | n/a | n/a | -US$89m |
| Mar 31 2024 | n/a | n/a | -US$106m |
| Dec 31 2023 | US$4m | US$545k | -US$87m |
| Sep 30 2023 | n/a | n/a | -US$77m |
| Jun 30 2023 | n/a | n/a | -US$75m |
| Mar 31 2023 | n/a | n/a | -US$73m |
| Dec 31 2022 | US$698k | US$470k | -US$74m |
| Sep 30 2022 | n/a | n/a | -US$73m |
| Jun 30 2022 | n/a | n/a | -US$78m |
| Mar 31 2022 | n/a | n/a | -US$73m |
| Dec 31 2021 | US$2m | US$460k | -US$71m |
| Sep 30 2021 | n/a | n/a | -US$75m |
| Jun 30 2021 | n/a | n/a | -US$39m |
| Mar 31 2021 | n/a | n/a | -US$45m |
| Dec 31 2020 | US$2m | US$467k | -US$68m |
| Sep 30 2020 | n/a | n/a | -US$87m |
| Jun 30 2020 | n/a | n/a | -US$130m |
| Mar 31 2020 | n/a | n/a | -US$149m |
| Dec 31 2019 | US$2m | US$445k | -US$149m |
Ersättning vs marknad: Dan s total kompensation ($USD 2.40M ) är ungefär genomsnittet för företag av liknande storlek på US marknaden ($USD 2.41M ).
Ersättning vs inkomst: Ersättningen från Dan har varit i linje med företagets resultat under det senaste året.
VD OCH KONCERNCHEF
Dan Paterson (65 yo)
7.1yrs
Anställning
US$2,400,525
Kompensation
Mr. Daniel W. Paterson, also known as Dan, serves as Chief Executive Officer Verastem, Inc. since August 1, 2023 and is its President of Verastem, Inc. since June 2019. He is Director of Verastem, Inc. sin...
Ledningsgrupp
| Namn | Position | Anställning | Kompensation | Ägarskap |
|---|---|---|---|---|
| President | 7.1yrs | US$2.40m | 0.28% $ 1.5m | |
| Chief Financial Officer | 3.8yrs | US$976.87k | 0.068% $ 360.4k | |
| President of Development & Director | less than a year | US$1.21m | 0.017% $ 91.5k | |
| Co-Founder & Chair of Scientific Advisory Board | no data | inga uppgifter | inga uppgifter | |
| Co-Founder | no data | inga uppgifter | inga uppgifter | |
| Executive Vice President of Portfolio Strategy & Operations | less than a year | inga uppgifter | inga uppgifter | |
| Chief Scientific Officer | 10.3yrs | US$319.51k | inga uppgifter | |
| Vice President of Corporate Communications & Investor Relations | no data | inga uppgifter | inga uppgifter | |
| Senior VP of Legal & Chief Compliance Officer | less than a year | inga uppgifter | inga uppgifter | |
| Chief Organizational Effectiveness Officer | no data | inga uppgifter | inga uppgifter | |
| Chief Business Officer | 2.5yrs | inga uppgifter | inga uppgifter | |
| Global Head of Regulatory Affairs & Development | 2.5yrs | inga uppgifter | inga uppgifter |
2.5yrs
Genomsnittlig anställningstid
63yo
Genomsnittlig ålder
Erfaren ledning: VSTM s ledningsgrupp anses vara erfaren ( 2.5 års genomsnittlig anställningstid).
Styrelseledamöter
| Namn | Position | Anställning | Kompensation | Ägarskap |
|---|---|---|---|---|
| President | 3yrs | US$2.40m | 0.28% $ 1.5m | |
| President of Development & Director | 13.7yrs | US$1.21m | 0.017% $ 91.5k | |
| Co-Founder & Chair of Scientific Advisory Board | no data | inga uppgifter | inga uppgifter | |
| Member of Scientific Advisory Board | no data | inga uppgifter | inga uppgifter | |
| Independent Director | 5.1yrs | US$192.99k | 0.0095% $ 50.4k | |
| Independent Director | 9.2yrs | US$214.99k | 0.019% $ 100.9k | |
| Independent Chairman | 6.3yrs | US$199.99k | 0.019% $ 100.9k | |
| Member of Scientific Advisory Board | 4.3yrs | inga uppgifter | inga uppgifter | |
| Director | 8.8yrs | US$202.99k | 0.16% $ 829.7k | |
| Independent Director | 3.8yrs | US$209.99k | 0.019% $ 100.9k | |
| Independent Director | 4.7yrs | US$202.99k | 0.019% $ 100.9k | |
| Independent Director | 3.2yrs | US$197.99k | 0.019% $ 100.9k |
4.9yrs
Genomsnittlig anställningstid
66yo
Genomsnittlig ålder
Erfaren styrelse: VSTM s styrelse anses vara erfaren ( 4.9 års genomsnittlig mandatperiod).
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/07/27 20:29 |
| Aktiekurs vid dagens slut | 2026/07/27 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Verastem, Inc. bevakas av 28 analytiker. 9 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| Matthew Cross | Alliance Global Partners |
| George Zavoico | B. Riley Securities, Inc. |